. . "Pimecrolimus is an immunomodulating agent used in the treatment of atopic dermatitis (eczema). It is currently available as a topical cream, once marketed by Novartis, (however Galderma will be promoting the molecule in Canada in early 2007) under the trade name Elidel. [Wikipedia]"@en . "Pimecrolimus"@en . . . " "@en . "approved"@en . . . . "Pimecrolimusum"@en . . . . "investigational"@en . . . . . . "Because of the low systemic absorption of pimecrolimus following topical application the calculation of standard pharmacokinetic measures such as AUC, C_max, half-life, etc. cannot be reliably done."@en . . "74%-87% (in vitro, bound to plasma proteins)"@en . . . . . . . . . "Side effects include burning sensation, irritation, pruritus, erythema, and skin infections, at the application site."@en . . . "80% of the drug is excreted in the feces."@en . . "137071-32-0"@en . . "Humans and other mammals"@en . "33-Epi-chloro-33-desoxyascomycin"@en . "Viktor Gyollai, Csaba Szabo, \"Methods of preparing pimecrolimus.\" U.S. Patent US20060142564, issued June 29, 2006."@en . . . . . . . . . . . . "Pimecrolimus"@en . . . . . . . "# Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G: A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999 Aug;141(2):264-73. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10468798"@en . . . . . . . . "Pimecrolimus binds with high affinity to macrophilin-12 (FKBP-12) and inhibits the calcium-dependent phosphatase, calcineurin. As a consequence, it inhibits T cell activation by blocking the transcription of early cytokines. In particular, pimecrolimus inhibits at nanomolar concentrations Interleukin-2 and interferon gamma (Th1-type) and Interleukin-4 and Interleukin-10 (Th2-type) cytokine synthesis in human T cells. Also, pimecrolimus prevents the release of inflammatory cytokines and mediators from mast cells in vitro after stimulation by antigen/lgE."@en . . . "For treatment of mild to moderate atopic dermatitis."@en .